SG3199-Val-Ala-PAB

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway:	HY-101152 1595275-61-8 C ₄₉ H ₅₉ N ₇ O ₁₁ 922.03 Drug-Linker Conjugates for ADC Antibody-drug Conjugate/ADC Related	$H_{0}N_{0} + \int_{0}^{H_{0}} H_{0} + \int_{0}^{H_{0}} H_{0} + \int_{0}^{H_{0}} \int_{0}^{H_{0}}$
Storage:	-20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)	

SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg	
	Preparing Stock Solutions	1 mM	1.0846 mL	5.4228 mL	10.8456 mL	
		5 mM	0.2169 mL	1.0846 mL	2.1691 mL	
		10 mM	0.1085 mL	0.5423 mL	1.0846 mL	
	Please refer to the so	lubility information to select the app	propriate solvent.			
In Vivo		1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 3.25 mg/mL (3.52 mM); Clear solution				
		2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 3.25 mg/mL (3.52 mM); Clear solution				

BIOLOGICAL ACTIVITY				
BIOLOGICAL ACTIVITY				
Description	SG3199-Val-Ala-PAB is an intermediate of Tesirine synthesis. Tesirine is a agent-linker conjugate for ADC which can be used for the research of several cancers ^[1] .			
In Vitro	SG3199-Val-Ala-PAB is an intermediate in in the synthesis of Tesirine, an antibody-drug conjugate pyrrolobenzodiazepine dimer payload ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

REFERENCES



[1]. Tiberghien AC, et, al. Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload. ACS Med Chem Lett. 2016 May 24;7(11):983-987.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA